Learning Documentation Lessons from FDA/EMA Inspections - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Learning Documentation Lessons from FDA/EMA Inspections

Source: Applied Clinical Trials

The Association of Clinical Research Professionals (ACRP) is organizing an online teaching session about regulatory inspections, to be held on May 14, 2014.

The event will examine common findings from inspections by the Food and Drug Administration (FDA) and European Medicines Agency (EMA). The plan is to use a “lessons learned” approach to help identify and prevent common inspection findings related to essential document collection and retention.

According to a statement from the organizers, “This Webinar delves into essential document collection and retention by first identifying what essential documents are and why they are necessary. The presenter will then cover essential document requirements and responsibilities in clinical research, followed by essential document retention requirements.”

Also, the program will cover any differences between ICH/GCP, FDA, and the EU Clinical Trials Directive in the requirements and retention of essential documents.

The event is designed for experienced research nurses, investigators, research assistants, research associates, project managers and all other staff who are directly involved in performing clinical research who are familiar with the terminology. The presenter will be Judith van Heel, who formerly worked for Bristol Myers-Squibb and Novartis and CROs Kendle International and JCR).

The event will take place from 12 noon to 1.30 pm US Eastern Time. The cost of registration is $99 for members and $149 for non-members.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here